BRAF Mutations in Canine Cancers
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Activating mutations of the BRAF gene lead to constitutive activation of the MAPK pathway. Although many human cancers carry the mutated BRAF gene, this mutation has not yet been characterized in canine cancers. As human and canine cancers share molecular abnormalities, we hypothesized that BRAF gene mutations also exist in canine cancers. To test this hypothesis, we sequenced the exon 15 of BRAF, mutation hot spot of the gene, in 667 canine primary tumors and 38 control tissues. Sequencing analysis revealed that a single nucleotide T to A transversion at nucleotide 1349 occurred in 64 primary tumors (9.6%), with particularly high frequency in prostatic carcinoma (20/25, 80%) and urothelial carcinoma (30/45, 67%). This mutation results in the amino acid substitution of glutamic acid for valine at codon 450 (V450E) of canine BRAF, corresponding to the most common BRAF mutation in human cancer, V600E. The evolutional conservation of the BRAF V600E mutation highlights the importance of MAPK pathway activation in neoplasia and may offer opportunity for molecular diagnostics and targeted therapeutics for dogs bearing BRAF-mutated cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 3×
“Constitutive activation of MAPK signaling by activating mutations of BRAF (~60%) or NRAS (~15%) genes plays an important role in the pathogenesis of human melanoma [4,5,11,12].”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“Recently, vemurafenib and dabrafenib, selective BRAF inhibitors, improved clinical outcomes in patients with melanoma compared to conventional chemotherapy [34,35].”
BackgroundIntegrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701 · cited 1×
“Although BRAF V600E mutations are infrequent in humans [24–26], accumulating evidence suggests that MAPK pathway plays an important role in the development and progression of human PC, especially in metastatic tumors [27].”
BackgroundMAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 8×
“This amino acid change corresponds to the human V600E mutation (Fig 1).”
BackgroundInfluentialHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989 · cited 1×
“Recently, vemurafenib and dabrafenib, selective BRAF inhibitors, improved clinical outcomes in patients with melanoma compared to conventional chemotherapy [34,35].”
BackgroundLiquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210 · cited 1×
“Detection of BRAFmutations can be used as a means to diagnose and monitor tumor burden in liquid samples, such as blood or urine, without necessitating biopsy of tumors (called as liquid biopsy, reviewed in [32,33]).”
BackgroundLiquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819 · cited 1×
“Detection of BRAFmutations can be used as a means to diagnose and monitor tumor burden in liquid samples, such as blood or urine, without necessitating biopsy of tumors (called as liquid biopsy, reviewed in [32,33]).”
BackgroundKimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247 · cited 1×
“MAPK pathway), were found in>82% of human papillary UC, suggesting that activation of the pathway is a main driving factor for the subclass of human UC [21,22].”
BackgroundTargeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
BRAF Mutations in Hairy-Cell Leukemia
Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014209 · Cited by 1,024
BRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664
Haroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446286 · Cited by 537
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Mulholland, D. J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L. M., Huang, J., Gleave, M., & Wu, H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3132 · Cited by 478
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467 · cited 2×
“Constitutive activation of MAPK signaling by activating mutations of BRAF (~60%) or NRAS (~15%) genes plays an important role in the pathogenesis of human melanoma [4,5,11,12].”
BackgroundRearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 464 · cited 1×
“Additionally, recurrent chromosomal translocations involving RAS and RAF genes, which result in oncogenic fusion genes, were recently discovered in a subset (~5%) of human PC cases [29,30].”
BackgroundExamination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma
Goel, V. K., Lazar, A. J. F., Warneke, C. L., Redston, M. S., & Haluska, F. G. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700026 · Cited by 392 · cited 2×
“Constitutive activation of MAPK signaling by activating mutations of BRAF (~60%) or NRAS (~15%) genes plays an important role in the pathogenesis of human melanoma [4,5,11,12].”
BackgroundRAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376 · cited 1×
“The V600E mutation occurs within the activation segment of the gene and mimics phosphorylation, drastically elevating kinase activity and activation of the downstream signal [3,4].”
BackgroundProstate cancer in dogs: Comparative and clinical aspects
LeRoy, B. E., & Northrup, N. (2009) · The Veterinary Journal · doi:10.1016/j.tvjl.2008.07.012 · Cited by 227 · cited 2×
“A unique feature of canine PC is that the majority of tumors arise in androgen-independent manner, with increased risk in castrated dogs [23].”
BackgroundAbsence of BRAF mutations in UV-protected mucosal melanomas
Edwards, R. H., Ward, M. R., Wu, H., Medina, C. A., Brose, M. S., Volpe, P., Nussen-Lee, S., Haupt, H. M., Martin, A. M., Herlyn, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.016667 · Cited by 178 · cited 1×
“In human melanoma, the presence of BRAFmutation is associated with skin exposure to UV light, and melanomas on mucosal sites or non-UV-exposed skin rarely possess the mutation [18,19].”
BackgroundNaturally occurring melanomas in dogs as models for non‐UV pathways of human melanomas
Gillard, M., Cadieu, E., De Brito, C., Abadie, J., Vergier, B., Devauchelle, P., Degorce, F., Dréano, S., Primot, A., Dorso, L., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12170 · Cited by 174 · cited 1×
“This mutation was not identified in previous studies of canine melanoma [13,17], likely due the low frequency of the BRAFmutation in canine melanoma.”
BackgroundGao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141 · cited 1×
“Activation of BRAF/MAPK signaling makes human PC tumor cells less dependent on androgen for proliferation in vivo and in vitro, contributing to hormone-refractory phenotype [31].”
BackgroundUnderstanding urothelial carcinoma through cancer pathways
Schulz, W. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21852 · Cited by 118
Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
Wang, X.-S., Shankar, S., Dhanasekaran, S. M., Ateeq, B., Sasaki, A. T., Jing, X., Robinson, D., Cao, Q., Prensner, J. R., Yocum, A. K., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0022 · Cited by 106 · cited 1×
“Additionally, recurrent chromosomal translocations involving RAS and RAF genes, which result in oncogenic fusion genes, were recently discovered in a subset (~5%) of human PC cases [29,30].”
BackgroundBRAF and KRAS mutations in prostatic adenocarcinoma
Cho, N., Choi, M., Kim, B., Cho, Y., Moon, K. C., & Kang, G. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22071 · Cited by 94
Fowles, J. S., Denton, C. L., & Gustafson, D. L. (2013) · Veterinary and Comparative Oncology · doi:10.1111/vco.12044 · Cited by 88
Rapid response of biallelic BRAF V 600 E mutated hairy cell leukaemia to low dose vemurafenib
Follows, G., Sims, H., Bloxham, D. M., Zenz, T., Hopper, M. A., Liu, H., Bench, A. J., Wright, P., Veer, M. B. V., & Scott, M. A. (2012) · British Journal of Haematology · doi:10.1111/bjh.12201 · Cited by 70
Munoz, J. L., Schlette, E. J., & Kurzrock, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.7739 · Cited by 69
Mutational Analysis of the BRAF Gene in Transitional Cell Carcinoma of the Bladder
Boulalas, I., Zaravinos, A., Delakas, D., & Spandidos, D. A. (2009) · The International Journal of Biological Markers · doi:10.5301/jbm.2009.4457 · Cited by 64 · cited 1×
“Interestingly, canine UC showed much higher frequency of the BRAFmutation than is reported to in human UC tumors [20].”
BackgroundExon 15 BRAF mutations are uncommon in canine oral malignant melanomas
Shelly, S., Chien, M. B., Yip, B., Kent, M. S., Théon, A. P., McCallan, J. L., & London, C. A. (2005) · Mammalian Genome · doi:10.1007/s00335-004-2441-x · Cited by 59 · cited 2×
“Similarly, constitutive activation of the MAPK pathway is implicated in canine melanoma [13,14], although RAS genes were infrequently mutated [14–16].”
BackgroundRen, G., Liu, X., Mao, X., Zhang, Y., Stankiewicz, E., Hylands, L., Song, R., Berney, D. M., Clark, J., Cooper, C., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21984 · Cited by 50
Upregulation of the PI3K/Akt Pathway in the Tumorigenesis of Canine Thyroid Carcinoma
Campos, M. A. L., Kool, M. M. J., Daminet, S., Ducatelle, R., Rutteman, G. R., Kooistra, H. S., Galac, S., & Mol, J. A. (2014) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12435 · Cited by 45
Köllermann, J. W., ALBRECHT, H., Schlomm, T., Huland, H., Graefen, M., Bokemeyer, C., SIMON, R., Sauter, G., & Wilczak, W. (2010) · Oncology Letters · doi:10.3892/ol_00000127 · Cited by 18
Metadata
- Authors
- Mochizuki, H., Kennedy, K., Shapiro, S. G., & Breen, M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-06-08
- Volume
- 10
- Issue
- 6
- Pages
- e0129534
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W569838262
- Cited by
- 159
- References
- 37
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.